Novartis Halts Development Of Antibiotic Booster Acquired In NeuTec Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug maker will take a $235 million charge in the third quarter as a result.
You may also be interested in...
Novartis Could Add To Its Hospital-Acquired Infection Portfolio With Acquisition
Proposed acquisition of NeuTec would give Novartis two Phase III therapies for its nosocomial arsenal.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.